Valuation: ME Therapeutics Holdings Inc.

Market Cap 75.97M 53.51M 47.76M 44.39M 40.38M 5.07B 77.34M 533M 209M 2.64B 201M 197M 8.46B P/E 2024
-51.7x
P/E 2025 -93.2x
Enterprise Value 74.64M 52.57M 46.93M 43.62M 39.67M 4.98B 75.99M 524M 205M 2.6B 197M 193M 8.31B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
44.63%
Yield 2024 *
-
Yield 2025 -
1 day+12.50%
1 week-35.71%
Current month-35.71%
1 month-40.00%
3 months-9.55%
6 months-28.00%
Current year-55.00%
1 week 1.51
Extreme 1.51
1.8
1 month 1.51
Extreme 1.51
2.8
Current year 0.79
Extreme 0.79
4.1
1 year 0.79
Extreme 0.79
8
3 years 0.05
Extreme 0.05
11
5 years 0.05
Extreme 0.05
11
10 years 0.05
Extreme 0.05
11
Manager TitleAgeSince
Chief Executive Officer 46 08/03/2023
Director of Finance/CFO 44 08/03/2023
Corporate Secretary 46 08/03/2023
Director TitleAgeSince
Director/Board Member 60 08/03/2023
Director/Board Member 46 08/03/2023
Director/Board Member 59 08/03/2023
Date Insider Type Main position Quantity % Market Cap. Importance
16/07/26 Option

Director

294,118 0.9788%
16/07/26 Sell

Director

294,118 0.9788%
16/07/26 Option

Chief Financial Officer

125,000 0.4160%
Change 5-day change 1-year change 3-year change Capi.($)
+12.50%-35.71%-56.10%+182.35% 34.06M
+0.21%-4.63%+55.34%+71.32% 68.92B
+1.66%-9.54%+10.39%+60.04% 51.9B
+3.14%+4.61%+15.36%+44.42% 48.73B
+3.45%+4.70%+33.44%+35.96% 43.13B
-2.20%+0.61%+281.88%+532.76% 41.48B
+6.43%+6.84%+18.32%+109.23% 39.96B
+1.28%-0.76%+12.67%+45.10% 30.6B
-2.21%-14.22%+40.33%-0.94% 26.01B
+1.74%-2.02%-13.55%-12.92% 22.27B
Average +2.60%-5.19%+39.81%+106.73% 37.3B
Weighted average by Cap. +1.58%-3.12%+53.89%+105.31%

Financials

2024 2025
Net sales - -
Net income -1.29M -912K -814K -757K -688K -86.37M -1.32M -9.09M -3.56M -45.06M -3.42M -3.35M -144M -1.19M -840K -750K -697K -634K -79.6M -1.21M -8.38M -3.28M -41.53M -3.15M -3.09M -133M
Net Debt -1.5M -1.05M -941K -875K -796K -99.85M -1.52M -10.51M -4.11M -52.1M -3.96M -3.87M -167M -1.33M -938K -837K -778K -708K -88.81M -1.36M -9.34M -3.66M -46.34M -3.52M -3.44M -148M
Projected Income Statement - Annual - ME Therapeutics Holdings Inc.
Logo ME Therapeutics Holdings Inc.
ME Therapeutics Holdings Inc. is a preclinical stage biotechnology company involved in the discovery and development of novel immune oncology therapeutics targeting immune suppression in cancer. The Company’s focus is on overcoming the suppressive effects of a class of immune cells called myeloid cells to enhance anti-cancer immunity. The Company’s lead candidate is a novel high affinity antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. In addition to its antibody drug candidate program, the Company is also developing a novel small molecule prodrug candidate designed to specifically target suppressive myeloid cells in the tumor environment. The Company has initiated design and testing of two new mRNA-based cancer therapeutic drug candidates.
Employees
-
Date Price Change Volume
15/10/26 CA$1.800 +12.50% 200
14/10/26 CA$1.600 -42.86% 4,020
08/10/26 CA$2.800 +40.00% 500
  1. Stock Market
  2. Stocks
  3. METX Stock